Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
5 stopped studies mapped to Endometrial Clear Cell Adenocarcinoma and descendants · 100% state a reason
Over the 5 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02874430 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or… | Phase 2 | terminated | Aug 22, 2016 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | study closed early due to slow accrual | Enrollment / accrual |
| NCT04906382 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | Early Phase 1 | terminated | May 28, 2021 | Floor Backes, MD | Sponsor reorganization | Other (stated, no rule matched) |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube,… | Phase 2 | terminated | Feb 11, 2014 | National Cancer Institute (NCI) | Interim monitoring | Other (stated, no rule matched) |
| NCT03836157 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | Phase 2 | withdrawn | Feb 11, 2019 | University of Oklahoma | Study was not initiated. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Apr 22, 2026source: clinicaltrials